The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2026

Filed:

Dec. 23, 2021
Applicants:

Children's Hospital Medical Center, Cincinnati, OH (US);

The United States of America, As Represented BY the Secretary, Dept. of Health and Human Services, Bethesda, MD (US);

Kurome Therapeutics, Inc., Cincinnati, OH (US);

Inventors:

Scott Bryan Hoyt, Arlington, VA (US);

Craig Joseph Thomas, Gaithersburg, MD (US);

Daniel T. Starczynowski, Cincinnati, OH (US);

Jan Susan Rosenbaum, Cincinnati, OH (US);

Gabriel Gracia Maldonado, Aguadilla, PR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/541 (2006.01); A61K 31/635 (2006.01); A61P 35/02 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/541 (2013.01); A61K 31/635 (2013.01); A61P 35/02 (2018.01); C07D 519/00 (2013.01);
Abstract

Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.


Find Patent Forward Citations

Loading…